The House Oversight and Government Reform Committee is undeterred from its quest at uncovering exactly how much profit Canonsburg, Pa.-based Mylan makes on its EpiPen sales.
On Monday, the congressional committee sent Mylan a letter requesting 18 different sets of information regarding the profitability of EpiPens, reports CNBC.
The letter suggests CEO Heather Bresch veiled Mylan's tax assumptions for EpiPen when she appeared before the committee in a hearing last month. Ms. Bresch told lawmakers the company makes $100 off a two-pack of EpiPens listed at $608. However, this estimate accounts for a U.S. tax rate of 37.5 percent. Since Mylan is incorporated overseas, it pays a lower tax rate.
"We remain committed to productive and continued cooperation with the committee, and we intend to respond to their request for additional information," a Mylan spokeswoman told CNBC in response to the letter.
Mylan has until Friday to provide the requested information.
More articles on supply chain:
5 drugs awaiting FDA review in October
Coastal hospitals prepare supplies for Hurricane Matthew
DEA slashes opioid manufacturing quotas by 25% for 2017